Literature DB >> 22004871

Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and β-cell differentiation in streptozocin-induced diabetic mice.

Jennifer H Ho1, Tzu-Ching Tseng, Wei-Hsien Ma, Wei-Kee Ong, Yu-Fan Chen, Ming-Hsiang Chen, Ming-Wei Lin, Chuang-Ye Hong, Oscar K Lee.   

Abstract

Depletion of pancreatic β-cells results in insulin insufficiency and diabetes mellitus (DM). Single transplantation of mesenchymal stem cells exhibits short-term effects in some preclinical studies. Here, we further investigated the long-term therapeutic effects of multiple intravenous MSC transplantations. In this study, multiple human MSC transplantations (4.2 × 10(7) cells/kg each time) were performed intravenously at 2-week intervals into streptozocin (STZ)-induced diabetic mice for 6 months. Blood sugar, insulin, renal function, cholesterol, and triglyceride levels were monitored. We demonstrated that compared to single intravenous transplantation, which only transiently decreased hyperglycemia, multiple MSC transplantations effectively restored blood glucose homeostasis. Systemic oxidative stress levels were reduced from the seventh week of treatment. From the 11th week, production of human insulin was markedly increased. When MSC transplantation was skipped after blood sugar level returned to normal at the end of 15th week, a sharp rebound of blood sugar occurred, and was then controlled by subsequent transplantations. At the end of 6 months, histopathology examination revealed MSCs specifically engrafted into liver tissues of the recipients. Fifty-one percent of human cells in the recipient liver coexpressed human insulin, especially those surrounding the central veins. Taken together, intravenous MSC delivery was safe and effective for blood glucose stabilization in this preclinical DM model. Multiple transplantations were essential to restore and maintain glucose homeostasis through decreasing systemic oxidative stress in the early stage and insulin production in the late stage. Liver engraftment and differentiation into insulin-producing cells account for the long-term therapeutic effects of MSCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004871     DOI: 10.3727/096368911X603611

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  32 in total

Review 1.  Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation.

Authors:  Jiang Li; Mohamed B Ezzelarab; David K C Cooper
Journal:  Xenotransplantation       Date:  2012 Sep-Oct       Impact factor: 3.907

2.  Ginkgo biloba L. extract enhances the effectiveness of syngeneic bone marrow mesenchymal stem cells in lowering blood glucose levels and reversing oxidative stress.

Authors:  Ming Ren; Shujuan Yang; Jianhui Li; Yulin Hu; Zhixing Ren; Shuping Ren
Journal:  Endocrine       Date:  2012-07-20       Impact factor: 3.633

3.  Immunogenicity of allogeneic mesenchymal stem cells transplanted via different routes in diabetic rats.

Authors:  Le-Hui Gu; Tian-Tian Zhang; Yang Li; Hong-Jie Yan; Hui Qi; Fu-Rong Li
Journal:  Cell Mol Immunol       Date:  2014-09-22       Impact factor: 11.530

4.  Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro.

Authors:  Lindsay C Davies; Jessica J Alm; Nina Heldring; Guido Moll; Caroline Gavin; Ioannis Batsis; Hong Qian; Mikael Sigvardsson; Bo Nilsson; Lauri E Kyllonen; Kaija T Salmela; Per-Ola Carlsson; Olle Korsgren; Katarina Le Blanc
Journal:  Stem Cells Transl Med       Date:  2016-07-13       Impact factor: 6.940

5.  Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes.

Authors:  Jianxia Hu; Yangang Wang; Huimin Gong; Chundong Yu; Caihong Guo; Fang Wang; Shengli Yan; Hongmei Xu
Journal:  Exp Ther Med       Date:  2016-07-26       Impact factor: 2.447

6.  Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells.

Authors:  Levilester Salcedo; Marc Penn; Margot Damaser; Brian Balog; Massarat Zutshi
Journal:  Stem Cells Transl Med       Date:  2014-05-05       Impact factor: 6.940

7.  Roles of Wnt/β-catenin signaling in retinal neuron-like differentiation of bone marrow mesenchymal stem cells from nonobese diabetic mice.

Authors:  Xu Yue; Gu Zhifeng; Shen Biyu; Xu Guofeng; Zhou Tianqiu; Jiang Jinxia; Xing Jing; Liu Suzhe; Li Man; Tan Wei; Feng Guijuan; Sang Aimin; Li Liren
Journal:  J Mol Neurosci       Date:  2012-11-16       Impact factor: 3.444

8.  Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.

Authors:  Jianxia Hu; Fang Wang; Ruixia Sun; Zhongchao Wang; Xiaolong Yu; Li Wang; Hong Gao; Wenjuan Zhao; Shengli Yan; Yangang Wang
Journal:  Endocrine       Date:  2013-05-18       Impact factor: 3.633

Review 9.  Impact of Diabetes Mellitus on Human Mesenchymal Stromal Cell Biology and Functionality: Implications for Autologous Transplantation.

Authors:  Marwa Mahmoud; Nourhan Abu-Shahba; Osama Azmy; Nagwa El-Badri
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

10.  Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats.

Authors:  Li Zhang; Kanghua Li; Xiangfei Liu; Diangeng Li; Congjuan Luo; Bo Fu; Shaoyuan Cui; Fei Zhu; Robert Chunhua Zhao; Xiangmei Chen
Journal:  Stem Cells Dev       Date:  2013-08-21       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.